← boardnext 2026-12-31next 2027-04
MNOV
MediciNovadistress 1/10 · well-funded / low risk$1.32-1%today-30% from 52w high
Lead: Amyotrophic Lateral Sclerosis
Revenue
pre-revenue
Liquidity
$77M
Runway
8.1 yrs
Shares 1y
+0%
Price & events
-20.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.8%
1D
-7.0%
1W
-2.9%
1M
-3.6%
3M
-29.0%
6M
+4.8%
1Y
+0.0%
2Y
-64.6%
5Y
-75.0%
All
Overview
- Market Cap
- $64.97M
- Volume
- 16.28K
- 52 Week Range
- $1.18 – $1.88
- Total Shares
- 49.22M
- Float Shares
- 42.26M
- Short %
- 0.43%
- % Held by Insiders
- 2.88%
- % Held by Institutions
- 11.04%
- RVOL
- 0.25x
- Beta
- 0.62
Pipeline stages · 2 programs
MN-001
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
MN-166
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12-31 Estimated 50% readout ~2027-02-14 | Phase 2 | MN-001 | Diabetes Mellitus, Type 2, Hypertriglyceridemia, Non-Alcoholic Fatty Liver Disease | — | active not recruiting |
| 2027-04 Estimated 50% readout ~2027-06-15 | Phase 2/3 | MN-166fast trackorphan | Amyotrophic Lateral Sclerosis | — | active not recruiting |
Catalyst news & presentations · 2
- 2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
- 2Q 2025trial initiationsecondaryMN-166 · NIH-funded expanded access study (SEA-NOBI-ALS) to enroll first patient.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $9 (+582% upside) · 3 analysts
- 2026-05-04D. Boral CapitalBuy
- 2026-03-16HC Wainwright & Co.Buy
- 2026-01-30D. Boral CapitalBuy
- 2025-12-18D. Boral CapitalBuy
- 2025-12-08D. Boral CapitalBuy
- 2025-11-04D. Boral CapitalBuy
Competitors — Amyotrophic Lateral Sclerosis
- NVSEFNOVARTIS AG$292.0B · D3
- REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
- ARGXARGENX SE$54.3B · D0
- BIIBBIOGEN INC.$29.2B · D2
- ARWRARROWHEAD PHARMACEUTICALS, INC.$12.3B · D3
- CORTCORCEPT THERAPEUTICS INC$10.0B · D0
- QUREuniQure N.V.$2.5B · D5
- COYACoya Therapeutics, Inc.$101M · D3
- LONALeonaBio, Inc.$71M · D6
- BCLIBRAINSTORM CELL THERAPEUTICS INC.$12M · D8
Recent news
- 2026-07-23Enterprise value to EBIT forward of MediciNova, Inc. – TSE:4875 - TradingView
- 2026-07-22MediciNova stock trades steady as investors weigh recent losses and pipeline progress - Ad-hoc-news.de
- 2026-07-21MediciNova stock trades steady as pipeline progress contrasts with lower recent revenues - Ad-hoc-news.de
- 2026-07-15MediciNova reaches 200-patient enrollment in ALS study - Investing.com UK
- 2026-07-15MediciNova reaches 200-patient enrollment in ALS study - Investing.com
- 2026-07-15MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients - Yahoo! Finance Canada
- 2026-07-15ALS patients ineligible for trials join MediciNova's 200-person study - Stock Titan
- 2026-07-07MediciNova Inc outlines its biotech pipeline as investors watch MN-166 progress - Ad-hoc-news.de
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.